【摘要】 目的　观察拉米夫定 (Lamivudine)对肝炎病毒 (HBV)感染者的疗效及安全性。方法　 2 3 7例HBV感染者随机分为两组 ,治疗组 12 8例用拉米夫定每日 15 0mg治疗 48W ,对照组 10 9例常规保肝治疗。治疗第 8、16、2 4、48周分别检测HBVM、HBVDLT半定量、ALT等。结果　治疗组第 8、16、2 4、48周HBVDNA阴转率分别为 5 2 3 %、82 0 %、96 1%、89 1%均高于对照组 (P <0 0 5 ) ;治疗组HBeAg阴转率分别为 7 0 %、2 8 9%、71 9%、66 4%,后 3者高于对照组 (P <0 0 5 ) ;ALT复常率在第 8、16、48w分别为89 1%、97 7%、98 4%,后者高于对照组 (P <0 0 5 )。治疗组未发现明显拉米夫定相关性严重不良反应。结论　拉米夫定可有效降低患者血清HBVDNA水平 ,明显提高HBeAg阴转率 ,使ALT恢复正常 ,副反应轻而安全更多还原

【Abstract】 Objective To observe the efficacy and safety of lamivudine in the treatment of HBV infection. Methods 237 cases of HBV infection were divided into two groups randomly. 128 patients of group A were administered lamivudine 150mg a day for 48 weeks and routine nonspecific drugs. 109 patients of group B were administered only routine nonspecific drugs. HBV serological markers, HBV DLT and ALT were measured at 8th,16 th 24th,48th week. Results In the group A, HBV DNA negative conversion rates at 8th,16th,24th and 48th weeks after treatment were 52 3%,82 0%,96 1% and 89 1% respectively, which were higher than those in the group B(P<0 05). HBeAg negative conversion rates of group A at 8th,16th,24th,48th week were 7 0%,28 9%,71 9% and 66 4%resqectively, the latter three of which were higher then those in the group B(P<0 05). ALT normalization rates of group A at 8th,16th,48th weeks were 89 1%,97 7%,98 4%, and the latter was significantly higher as compared with that in the group A B(P<0 05).No serious side effect associated with lamivudine was observed. Conclusion Lamivudine could effectively clear serum HBV DNA increase HBeAg negative conversion rate and normalize ALT. Lamivudine was safe and its side effect was little.更多还原